Many biopharmaceutical companies and organizations have selected Crucell's PER.C6^® technology to develop their own products across a wide range of therapeutic areas. Crucell’s PER.C6^® technology is now used as a production platform for many vaccine, therapeutic protein, monoclonal antibody and gene therapy product programs.

PER.C6^® licensees – whether research or commercial – receive a high level of support from Crucell in their product development programs. Licensees receive qualified PER.C6^® cells for the establishment of new cell banks, have access to extensive know-how for use of PER.C6^® cells, and access to our technical support group and the PER.C6^® Extranet. 

For PER.C6^® technology licensees involved in development of recombinant proteins or antibodies, the PERCIVIA PER.C6^® Development Center offers support and a range of services. For further information visit www.percivia.com.

Crucell makes its PER.C6^® technology available to the industry under non-exclusive and, in selected cases, exclusive commercial licenses. Research licenses that may be converted into commercial licenses are also available.